Role of the RAS in pancreatic cancer

Current Cancer Drug Targets

Volumn 11, Issue 4, 2011, Pages 412-420

  Lau, S T ^a   Leung, P S ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Angiogenesis; Angiotensin II; Angiotensin II receotpr blocker (ARB); Angiotensin converting enzyme inhibitor (ACEI); Cytotoxicity; Pancreatic ductal adenocarcinoma (PDAC)

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BRUCEA JAVANICA EXTRACT; CAMPTOTHECIN; CHINESE DRUG; COPTIS RHIZOME EXTRACT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEMCITABINE;

ANGIOGENESIS; ANTIHYPERTENSIVE ACTIVITY; AUTOCRINE EFFECT; BLOOD PRESSURE REGULATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; ELECTROLYTE BALANCE; FLUID BALANCE; HUMAN; METASTASIS; NONHUMAN; PANCREAS CANCER; PARACRINE SIGNALING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 79955616775     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800911795538110     Document Type: Review

References (104)

1. Leung, P. S. The physiology of a local renin-angiotensin system in the pancrease. J. Physiol. 2007, 580, 31-37.
2. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. C.A. Cancer J. Clin. 2008, 58, 71-96.
3. Fujimoto, Y.; Sasaki, T.; Tsuchida, A.; Chayama, K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett. 2001, 495, 197-200.
4. Muscella, A.; Greco, S.; Elia, M. G.; Storelli, C.; Marsigliante, S. Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells. J. Endocrinol. 2002, 173, 315-323.
5. Le Noble, F. A.; Schreurs, N. H.; van Straaten, H. W.; Slaaf, D. W.; Smits, J. F., Rogg, H.; Struijker-Boudier, H. A. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am. J. Physiol. 1993, 264, R460-465.
6. Chua, C. C.; Hamdy, R. C.; Chua, B. H. Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim. Biophys. Acta. 1998, 1401, 187-194
7. Pupilli, C.; Lasagni, L.; Romagnani, P.; Bellini, F.; Mannelli, M.; Misciglia, N.; Mavilia, C.; Vellei, U.; Villari, D.; Serio, M. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J. Am. Soc. Nephrol. 1999, 10, 245-255.
8. Tamarat, R.; Silvestre, J. S.; Durie, M.; Levy, B. I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor-and inflammation-related pathways. Lab. Invest. 2002, 82, 747-756.
9. Corvol, P.; Jeunemaitre, X. Molecular genetics of human hypertension: role of angiotensinogen. Endocr. Rev. 1997, 18, 662-677.
10. Célérier, J.; Schmid, G.; Le Caer, J. P.; Gimenez-Roqueplo, A. P.; Bur, D.; Friedlein, A.; Langen, H.; Corvol, P.; Jeunemaitre, X. Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. J. Biol. Chem. 2000, 275, 10648-10654.
11. O'Reilly, M. S.; Pirie-Shepherd, S.; Lane, W. S.; Folkman, J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999, 285, 1926-1928.
12. Zhang, M.; Volpert, O.; Shi, Y. H.; Bouck, N. Maspin is an angiogenesis inhibitor. Nat. Med. 2000, 6, 196-199.
13. Dawson, D. W.; Volpert, O. V.; Gillis, P.; Crawford, S. E.; Xu, H.; Benedict, W.; Bouck, N. P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999, 285, 245-248.
14. Miao, R. Q.; Agata, J.; Chao, L.; Chao, J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002, 100, 3245-3252.
15. Brand, M.; Lamandé, N.; Larger, E.; Corvol, P.; Gasc, J. M. Angiotensinogen impairs angiogenesis in the chick chorioallantoic membrane. J. Mol. Med. 2007, 85, 451-60.
16. Bouquet, C.; Lamandé, N.; Brand, M.; Gasc, J. M.; Jullienne, B.; Faure, G.; Griscelli, F.; Opolon, P.; Connault, E.; Perricaudet, M.; Corvol, P. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol. Ther. 2006, 14, 175-182.
17. Nishizuka, Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature. 1988, 334, 661-665.
18. Suzuki, Y.; Ruiz-Ortega, M.; Lorenzo, O.; Ruperez, M.; Esteban, V.; Egido, J. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 2003, 35, 881-900.
19. Le Noble, F. A.; Hekking, J. W.; Van Straaten, H. W.; Slaaf, D. W.; Struyker Boudier, H. A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol. 1991, 195, 305-306.
20. Lee, J. M.; Lo, A. C.; Yang, S. Y.; Tsau, H. S.; Chen, R. J.; Lee, Y. C. Association of angiotensin-converting enzyme insertion/deletion polymorphism with serum level and development of pulmonary complications following esophagectomy. Ann. Surg. 2005, 241, 659-665.
21. Muramatsu, M.; Yamada, M.; Takai, S.; Miyazaki, M. Suppression of basic fibroblast growth factor-induced angiogenesis by a specific chymase inhibitor, BCEAB, through the chymase-angiotensindependent pathway in hamster sponge granulomas. Br. J. Pharmacol. 2002, 137, 554-560.
22. Lever, A. F.; Hole, D. J.; Gillis, C. R.; McCallum, I. R.; McInnes, G. T.; MacKinnon, P. L.; Meredith, P. A.; Murray, L. S.; Reid, J. L.; Robertson, J. W. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998, 352, 179-184.
23. Yasumaru, M.; Tsuji, S.; Tsujii, M.; Irie, T.; Komori, M.; Kimura, A.; Nishida, T.; Kakiuchi, Y.; Kawai, N.; Murata, H.; Horimoto, M.; Sasaki, Y.; Hayashi, N.; Kawano, S.; Hori, M. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway. Cancer Res. 2003, 63, 6726-6734.
24. Claffey, K. P.; Robinson, G. S. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev. 1996, 15, 165-176.
25. Elpek, G. O.; Gelen, T.; Aksoy, N. H.; Erdoǧan, A.; Dertsiz, L.; Demircan, A.; Keleş, N. The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus. J. Clin. Pathol. 2001, 54, 940-944.
26. Saito, H.; Tsujitani, S. Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res. 2001, 21, 4365-4372.
27. Tien, Y. W.; Chang, K. J.; Jeng, Y. M.; Lee, P. H.; Wu, M. S.; Lin, J. T.; Hsu, S. M. Tumor angiogenesis and its possible role in intravasation of colorectal epithelial cells. Clin. Cancer Res. 2001, 7, 1627-1632.
28. Pupilli, C.; Lasagni, L.; Romagnani, P.; Bellini, F.; Mannelli, M.; Misciglia, N.; Mavilia, C.; Vellei, U.; Villari, D.; Serio, M. Angiotensin II stimulates the synthesis and secretion of vascular permeability factor/vascular endothelial growth factor in human mesangial cells. J. Am. Soc. Nephrol. 1999, 10, 245-255.
29. Williams, B.; Baker, A. Q.; Gallacher, B.; Lodwick, D. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 1995, 25, 913-917.
30. Flamme, I.; Frölich, T.; Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell Physiol. 1997, 173, 206-210.
31. Risau, W. Mechanisms of angiogenesis. Nature 1997, 386, 671-674.
32. Zhang, L.; Hannay, J.A.; Liu, J.; Das, P.; Zhan, M.; Nguyen, T.; Hicklin, D. J.; Yu, D.; Pollock, R. E.; Lev, D. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res. 2006, 66, 8770-8778.
33. Cao, Y. Tumor angiogenesis and therapy. Biomed. Pharmacother. 2005, 59, S340-S343.
34. Wulff, C.; Wiegand, S. J.; Saunders, P. T.; Scobie, G. A.; Fraser, H. M. Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40). Endocrinology 2001, 142, 3244-3254.
35. Wulff, C.; Wilson, H.; Wiegand, S. J.; Rudge, J. S.; Fraser, H. M. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 2002, 143, 2797-2807.
36. Bernard-Marty, C.; Lebrun, F.; Awada, A.; Piccart, M. J. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006, 66, 1577-1591.
37. Timmermans, P. B.; Chiu, A. T.; Herblin, W. F.; Wong, P. C.; Smith, R. D. Angiotensin II receptor subtypes. Am. J. Hypertens. 1992, 5, 406-410.
38. Egami, K.; Murohara, T.; Shimada, T.; Sasaki, K.; Shintani, S.; Sugaya, T.; Ishii, M.; Akagi, T.; Ikeda, H.; Matsuishi, T.; Imaizumi, T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003, 112, 67-75.
39. De Paepe, B.; Verstraeten, V. L.; De Potter, C. R.; Vakaet, L. A.; Bullock, G. R. Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem. Cell Biol. 2001, 116, 247-254.
40. Silvestre, J. S.; Tamarat, R.; Senbonmatsu, T.; Icchiki, T.; Ebrahimian, T.; Iglarz, M.; Besnard, S.; Duriez, M.; Inagami, T.; Lévy, B. I. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia-induced angiogenesis in mice hindlimb. Circ. Res. 2002, 90, 1072-1079.
41. Efrati, S.; Berman, S.; Goldfinger, N.; Erez, N.; Averbukh, Z.; Golik, A.; Rotter, V.; Weissgarten, J. Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension. J. Hypertens. 2007, 25, 1041-1052.
42. Kobayashi, S.; Berisha, B.; Amselgruber, W. M.; Schams, D.; Miyamoto, A. Production and localisation of angiotensin II in the bovine early corpus luteum: a possible interaction with luteal angiogenic factors and prostaglandin F2 alpha. J. Endocrinol. 2001, 170, 369-380.
43. Suganuma, T.; Ino, K.; Shibata, K.; Kajiyama, H.; Nagasaka, T.; Mizutani, S.; Kikkawa, F. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin. Cancer Res. 2005, 11, 2686-2694.
44. Le Noble, F. A.; Hekking, J. W.; Van Straaten, H. W.; Slaaf, D. W.; Struyker Boudier, H. A. Angiotensin II stimulates angiogenesis in the chorio-allantoic membrane of the chick embryo. Eur. J. Pharmacol. 1991,195, 305-306.
45. le Noble, F. A.; Kessels-van Wylick, L. C.; Hacking, W. J.; Slaaf, D. W.; oude Egbrink, M. G.; Struijker-Boudier, H. A. The role of angiotensin II and prostaglandins in arcade formation in a developing microvascular network. J. Vasc. Res. 1996, 33, 480-488.
46. Wang, X. D.; Chen, X. M.; Wang, J. Z.; Hong, Q.; Feng, Z.; Fu, B.; Zhou, F.; Wang, F. Y.; Fan, D. M. Signal transducers and activators of transcription 3 mediates up-regulation of angiotensin II-induced tissue inhibitor of metalloproteinase-1 expression in cultured human senescent fibroblasts. Chin. Med. J. (Engl). 2006, 119, 1094-1102.
47. Chen, T. H.; Wang, J. F.; Chan, P.; Lee, H. M. Angiotensin II stimulates hypoxia-inducible factor 1alpha accumulation in glomerular mesangial cells. Ann. N.Y. Acad. Sci. 2005, 1042, 286-93.
48. Sánchez-López, E.; López, A. F.; Esteban, V.; Yagüe, S.; Egido, J.; Ruiz-Ortega, M.; Alvarez-Arroyo, M. V. Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. Antioxid. Redox Signal 2005, 7, 1275-1284.
49. Hii, S. I.; Nicol, D. L.; Gotley, D. C.; Thompson, L. C.; Green, M. K.; Jonsson, J. R. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br. J. Cancer 1998, 77, 880-883.
50. Volpert, O. V.; Ward, W. F.; Lingen, M. W.; Chesler, L.; Solt, D. B.; Johnson, M. D.; Molteni, A.; Polverini, P. J.; Bouck, N. P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996, 98, 671-679.
51. 1 angiotensin II receptor subtype in the human larynx and squamous laryngeal carcinoma. Cancer Lett. 1996, 110, 19-27.
52. Takeda, H.; Kondo, S. Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am. J. Pathol. 2001, 158, 1633-1637.
53. Gong, Q.; Davis, M.; Chipitsyna, G.; Yeo, C. J.; Arafat, H.A. Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 2010, 39, 581-594.
54. 1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma. Br. J. Cancer. 2001, 85, 1396-1399.
55. Chehl, N.; Gong, Q.; Chipitsyna, G.; Aziz, T.; Yeo, C. J.; Arafat, H. A. Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. J. Gastrointest. Surg. 2009, 13, 2189-2200.
56. Deshayes, F.; Nahmias, C. Angiotensin receptors: a new role in cancer? Trends Endocrinol. Metab. 2005, 16, 293-299.
57. Lam, K. Y. The pancreatic renin-angiotensin system: does it play a role in endocrine oncology. J.O.P. 2001, 2, 40-42.
58. Lam, K. Y.; Leung, P. S. Regulation and expression of a reninangiotensin system in human pancreas and pancreatic endocrine tumours. Eur. J. Endocrinol. 2002, 146, 567-572.
59. Anandanadesan, R.; Gong, Q.; Chipitsyna, G.; Witkiewicz, A.; Yeo, C. J.; Arafat, H. A. Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J. Gastrointest. Surg. 2008, 12, 57-66.
60. Arafat, H. A.; Gong, Q.; Chipitsyna, G.; Rizvi, A.; Saa, C. T.; Yeo, C. J. Antihypertensives as novel antineoplastics: angiotensin-Iconverting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J. Am. Coll. Surg. 2007, 204, 996-1005.
61. Jiang, H.; Li, Z. S.; Xu, G. M.; Tu, Z. X.; Gong, Y. F. Angiotensin II type 1 receptor mRNA and its protein expression in human pancreatic cancer cell lines. Chin. J. Dig. Dis. 2004, 5, 68-71.
62. Arrieta, O.; Guevara, P.; Escobar, E.; García-Navarrete, R.; Pineda, B.; Sotelo, J. Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br. J. Cancer. 2005, 92, 1247-1252.
63. Egami, K.; Murohara, T.; Shimada, T.; Sasaki, K.; Shintani, S.; Sugaya, T.; Ishii, M.; Akagi, T.; Ikeda, H.; Matsuishi, T.; Imaizumi, T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 2003, 112, 67-75.
64. Raizada, M. K.; Ferreira, A. J. ACE2: a new target for cardiovascular disease therapeutics. J. Cardiovasc. Pharmacol. 2007, 50, 112-119.
65. Mizuiri, S.; Hemmi, H.; Arita, M.; Ohashi, Y.; Tanaka, Y.; Miyagi, M.; Sakai, K.; Ishikawa, Y.; Shibuya, K.; Hase, H.; Aikawa, A. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am. J. Kidney. Dis. 2008, 51, 613-623.
66. Wang, G.; Lai, F. M.; Lai, K. B.; Chow, K. M.; Kwan, C. H.; Li, K. T.; Szeto, C. C. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 2008, 51, 1062-1067.
67. Zhou, L.; Zhang, R.; Yao, W.; Wang, J.; Qian, A.; Qiao, M.; Zhang, Y.; Yuan, Y. Decreased expression of angiotensinconverting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. Tohoku J. Exp. Med. 2009, 217, 123-13
68. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell. 2000, 100, 57-70.
69. Tortora, G.; Melisi, D.; Ciardiello, F. Angiogenesis: a target for cancer therapy. Curr. Pharm. Des. 2004, 10, 11-26.
70. Bruns, C. J.; Shrader, M.; Harbison, M. T.; Portera, C.; Solorzano, C. C.; Jauch, K. W.; Hicklin, D. J.; Radinsky, R.; Ellis, L. M. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int. J. Cancer. 2002, 102, 101-108.
71. Jia, L.; Zhang, M. H.; Yuan, S. Z.; Huang, W. G. Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J. Gastroenterol. 2005, 11, 47-450.
72. Laquente, B.; Lacasa, C.; Ginesta, M. M.; Casanovas, O.; Figueras, A.; Galan, M.; Ribas, I. G.; Germa, J. R.; Capella, G.; Vinals, F. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol. Cancer Ther. 2008, 7, 638-647.
73. Zhang, X.; Galardi, E.; Duquette, M.; Lawler, J.; Parangi, S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin. Cancer Res. 2005, 11, 5622-5630.
74. Korc, M. Pathways for aberrant angiogenesis in pancreatic cancer. Mol. Cancer 2001, 7, 2-8.
75. Kuroda, M.; Oka, T.; Oka, Y.; Yamochi, T.; Ohtsubo, K.; Mori, S.; Watanabe, T.; Machinami, R.; Ohnishi, S. Colocalization of vascular endothelial growth factor (vascular permeability factor) and insulin in pancreatic islet cells. J. Clin. Endocrinol. Metab. 1995, 80, 3196-200.
76. Büchler, P., Reber, H. A., Büchler, M. W., Friess, H., Hines, O. J. VEGF-RII influences the prognosis of pancreatic cancer. Ann. Surg. 2002, 236, 738-749.
77. Itakura, J.; Ishiwata, T.; Friess, H.; Fujii, H.; Matsumoto, Y.; Büchler, M. W.; Korc, M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 1997, 3, 1309-1316.
78. Itakura, J.; Ishiwata, T.; Shen, B.; Kornmann, M.; Korc, M. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 2000, 85, 27-34.
79. Seo, Y.; Baba, H.; Fukuda, T.; Takashima, M.; Sugimachi, K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88, 2239-2245.
80. Gupta, V. K.; Jaskowiak, N. T.; Beckett, M. A.; Mauceri, H. J.; Grunstein, J.; Johnson, R. S.; Calvin, D. A.; Nodzenski, E.; Pejovic, M.; Kufe, D. W.; Posner, M. C.; Weichselbaum, R. R. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J. 2002, 8, 47-54.
81. Harmey, J. H.; Bouchier-Hayes, D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002, 24, 280-283.
82. Hotz, H. G.; Reber, H. A.; Hotz, B.; Sanghavi, P. C.; Yu, T.; Foitzik, T.; Buhr, H. J.; Hines, O. J. Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J. Gastrointest. Surg. 2001, 5, 131-138.
83. Tokunaga, T.; Abe, Y.; Tsuchida, T.; Hatanaka, H.; Oshika, Y.; Tomisawa, M.; Yoshimura, M.; Ohnishi, Y.; Kijima, H.; Yamazaki, H.; Ueyama, Y.; Nakamura, M. Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int. J. Oncol. 2002, 21, 1027-1032.
84. Amaya, K.; Ohta, T.; Kitagawa, H.; Kayahara, M.; Takamura, H.; Fujimura, T.; Nishimura, G.; Shimizu, K.; Miwa, K. Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int. J. Oncol. 2004, 25, 849-856.
85. Bakkevold, K. E.; Arnesjo, B.; Dahl, O.; Kambestad, B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater-results of a controlled, prospective, randomised multicentre study. Eur. J. Cancer 1993, 29A, 698-703.
86. Carmeliet, P. Angiogenesis in health and disease. Nat. Med. 2003, 9, 653-660.
87. Rothenberg, M. L.; Moore, M. J.; Cripps, M. C.; Andersen, J. S.; Portenoy, R. K.; Burris, H. A.; Green, M. R.; Tarassoff, P. G.; Brown, T. D.; Casper, E. S.; Storniolo, A. M.; Von Hoff, D. D. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol. 1996, 7, 347-353.
88. Burris, H. A.; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
89. Stevenson, J. P.; Scher, R. M.; Kosierowski, R.; Fox, S. C.; Simmonds, M.; Yao, K. S.; Green, F.; Broom, C.; Fields, S. Z.; Krebs, J. B.; O'Dwyer, P. J. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur. J. Cancer 1998, 34, 1358-1362.
90. Scher, R. M.; Kosierowski, R.; Lusch, C.; Alexander, R.; Fox, S.; Redei, I.; Green, F.; Raskay, B.; Amfoh, K.; Engstrom, P. F.; O'Dwyer, P. J. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest. New Drugs 1996, 13, 347-354.
91. Wagener, D. J.; Verdonk, H. E.; Dirix, L. Y.; Catimel, G.; Siegenthaler, P.; Buitenhuis, M.; Mathieu-Boue, A.; Verweij, J. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol. 1995, 6, 129-132.
92. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A.; Campos, D.; Lim, R.; Ding, K.; Clark, G.; Voskoglou-Nomikos, T.; Ptasynski, M.; Parulekar, W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25, 1960-1966.
93. Fahy, B. N.; Schlieman, M. G.; Virudachalam, S.; Bold, R. J. Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer. J. Am. Coll. Surg. 2004, 198, 591-599
94. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer. Lancet 2004, 363, 1049-1057.
95. Okusaka, T.; Ito, Y.; Ueno, H.; Ikeda, M.; Takezako, Y.; Morizane, C.; Kagami, Y.; Ikeda, H. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br. J. Cancer 2004, 91, 673-677.
96. Lau, S. T.; Lin, Z. X.; Liao, Y.; Zhao, M.; Cheng, C. H.; Leung, P. S. Brucein D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. Cancer Lett. 2009, 281, 42-52.
97. Lau, S. T.; Lin, Z. X.; Zhao, M.; Leung, P. S. Brucea javanica fruit induces cytotoxicity and apoptosis in pancreatic adenocarcinoma cell lines. Phytother. Res. 2008, 22, 477-486.
98. Lau, S. T.; Lin, Z. X.; Leung, P. S. Role of reactive oxygen species in brucein D-mediated p38-mitogen-activated protein kinase and nuclear factor-kappaB signalling pathways in human pancreatic adenocarcinoma cells. Br. J. Cancer 2010, 102, 583-593.
99. Hara, A.; Lizuka, N.; Hamamoto, Y.; Uchimura, S.; Miyamoto, T.; Tsunedomi, R.; Miyamoto, K.; Hazama, S.; Okita, K.; Oka, M. Molecular dissection of a medicinal herb with anti-tumor activity by oligonucleotide microarray. Life Sci. 2005, 77, 991-1002.
100. Noguchi, R.; Yoshiji, H.; Kuriyama, S.; Yoshii, J.; Ikenaka, Y.; Yanase, K.; Namisaki, T.; Kitade, M.; Yamazaki, M.; Mitoro, A.; Tsujinoue, H.; Imazu, H.; Masaki, T.; Fukui, H. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin. Cancer Res. 2003, 9, 6038-6045.
101. Yoshiji, H.; Kuriyama, S.; Fukui, H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumor Biol. 2002, 23, 348-356.
102. Ocaranza, M. P.; Godoy, I.; Jalil, J. E.; Varas, M.; Collantes, P.; Pinto, M.; Roman, M.; Ramirez, C.; Copaja, M.; Diaz-Araya, G.; Castro, P.; Lavandero, S. Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 2006, 48, 572-578.
103. Igase, M.; Kohara, K.; Nagai, T.; Miki, T.; Ferrario, C. M. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens. Res. 2008, 31, 553-559.
104. Deplanque, G.; Harris, A. L. Anti-angiogenic agents: clinical trial design and therapies in development. Eur. J. Cancer. 2000, 36, 1713-1724.